Comparing first trimester screening performance: Routine care gynaecologists' practices vs. prenatal centre: FTS screening differences

Ultraschall in der Medizin

Volumn 28, Issue 3, 2007, Pages 291-295

  Kozlowski, P ^a   Knippel, A J ^a   Stressig, R ^a  

^a Praenatal Medizin und Genetik Düsseldorf ^*  (Germany)

Author keywords

Human chorionic gonadotropin; Nuchal translucency (NT); Pregnancy associated plasma protein A (PAPP A); Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CROWN RUMP LENGTH; DOWN SYNDROME; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; GYNECOLOGIC CARE; HUMAN; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; RISK FACTOR; TRISOMY 21;

BLOOD CHEMICAL ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DOWN SYNDROME; FEMALE; GYNECOLOGY; HUMANS; KARYOTYPING; MASS SCREENING; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL CARE; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 34447265293     PISSN: 01724614     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926714     Document Type: Article

References (14)

1. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821-829
2. Spencer K, Souter V, Tul N et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-237
3. Bindra R, Heath V, Liao A et al. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-225
4. Crossley J, Aitken D, Cameron A et al. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109: 667-676
5. Kaisenberg C von, Gasiorek-Wiens A, Bielicki M et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 2002; 12: 89-94
6. Spencer K, Spencer C, Power M et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003; 110: 281-286
7. Nicolaides KH, Spencer K, Avgidou K et al. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226
8. Braithwaite J, Kadir R, Pepera T et al. Nuchal translucency measurement: training of potential examiners. Ultrasound Obstet Gynecol 1996; 8: 192-195
9. Snijders R, Thom E, Zachary J et al. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353-359
10. Sancken U, Bahner D. The effect of thermal instability of intact human chorionic gonadotropin (ihCG) on the application of its free beta-subunit (free beta hCG) as a serum marker in Down syndrome screening. Prenat Diagn 1995; 15: 731-738
11. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998; 18: 519-523
12. Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. BJOG 2001; 108: 1043-1046
13. Snijders RJ, Noble P, Sebire N et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346
14. Merz E. Risk calculation of fetal chromosomal defects in the first trimester. Ultraschall in Med 2005; 26: 377-378